Clinical Trial Update: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1B dose-escalation and Phase 2a study of Carotuximab (TRC105) with Pazopanib in advanced soft tissue sarcoma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Carotuximab (carotuximab)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Advanced Soft Tissue Sarcoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-12